<DOC>
	<DOCNO>NCT00059761</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase I trial study effect body combine irinotecan cisplatin radiation therapy treat patient limited-stage small cell lung cancer could completely remove surgery .</brief_summary>
	<brief_title>Chemotherapy Combined With Radiation Therapy Treating Patients With Limited-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose irinotecan administer cisplatin thoracic radiotherapy ( give two different schedule ) patient limited stage small cell lung cancer . - Determine qualitative quantitative toxicity non-dose-limiting toxicity regimens patient . - Determine reversibility toxic effect associate regimens patient . OUTLINE : This non-randomized , dose-escalation study irinotecan . Patients assign 1 2 radiotherapy ( RT ) treatment group . - Radiotherapy : - Group I : Patients undergo thoracic RT twice daily , 5 day week , 3 week . - Group II : Patients undergo thoracic RT daily , 5 day week , 7 week . - Concurrent chemotherapy : Patients receive irinotecan IV 60-90 minute day 1 8 cisplatin IV 1 hour day 1 . Treatment repeat every 3 week 1 course group I 2 course group II . - Post RT chemotherapy : Patients receive irinotecan cisplatin 3 course group I 2 course , begin RT complete , group II . Sequential cohorts 6 patient per group receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month 1 year 6 month 4 year . PROJECTED ACCRUAL : A total 12-36 patient ( 6-18 per group ) accrue study within 18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer one two method : Fine needle aspiration biopsy Two positive sputum Must limit disease define follow : Stage IIIIB Confined 1 hemithorax No T4 tumor base malignant pleural pericardial effusion Patients pleural effusion small tap CT guidance evident chest xray allow No N3 disease base contralateral hilar contralateral supraclavicular involvement Measurable evaluable disease Tumor must able encompass specified radiotherapy field without unacceptable risk serious pulmonary compromise No complete tumor resection No pericardial effusion ( regardless cytology ) PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Absolute granulocyte count least 1,500/mm^3 Platelet count least 120,000/mm^3 Hepatic Bilirubin great 1.5 mg/dL No known Gilbert 's disease Renal Creatinine great 1.5 mg/dL Cardiovascular No myocardial infarction within past 6 month No symptomatic heart disease Pulmonary Forced expiratory volume ( FEV ) _1 least 1.0 L/sec No uncontrolled bronchospasms No uncompensated chronic obstructive pulmonary disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No preexist peripheral neuropathy grade 2 great No malignancy within past 2 year except curatively treat basal squamous cell skin cancer carcinoma situ bladder cervix No concurrent serious medical illness PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy No concurrent intensitymodulated radiotherapy Surgery See Disease Characteristics Other At least 7 day since prior enzymeinducing anticonvulsant drug ( EIACDs ) ( e.g. , phenytoin , carbamazepine , phenobarbital ) use regular basis 2 week Less 2 week regular use EIACDs require 7day washout period At least 14 day since prior Hypericum perforatum ( St. John 's wort ) No concurrent EIACDs No concurrent amifostine chemoradiotherapy Concurrent gabapentin nonEIACDs allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>limited stage small cell lung cancer</keyword>
</DOC>